EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 3.0

Use of Leflunomide in Renal Transplant Recipients with Ganciclovir-Resistant/Refractory Cytomegalovirus Infection: A Case Series from the University of Chicago

W James Chon, Pradeep V Kadambi, Chang Xu, Yolanda T Becker, Piotr Witkowski, Kenneth Pursell, Brenna Kane, Michelle A Josephson

Case Reports in Nephrology and Dialysis · 01.04.2015 · 5 (1) · 96-105

DOI: 10.1159/000381470 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Nephrology and Dialysis, online erschienen am 01.04.2015. Verfasst von W James Chon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Nephrology, University of Chicago, Chicago, Ill., USA. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although antiviral prophylaxis for cytomegalovirus (CMV) is widely used, CMV infection remains common in renal transplant recipients with adverse consequences.

Methods

We report 5 cases of renal transplant recipients with resistant CMV infection who were successfully managed with leflunomide at the University of Chicago Medical Center.

Results

Five renal transplant recipients (2 simultaneous pancreas/kidney transplants, 3 deceased donor kidney transplants) were diagnosed with GCV-resistant CMV infection from 2003 to 2011. Of the 4 patients who had resistance genotype testing, 3 showed a UL97 mutation and 1 patient had a clinically resistant CMV infection. All patients received CMV prophylaxis with valganciclovir for 3 months. The number of days from the date of transplant to viremia ranged from 38 to 458 days (median 219). All 5 patients received other antiviral agents (e.g. ganciclovir, foscarnet), and in 4 patients, viremia was cleared before leflunomide was initiated as consolidation (or maintenance) therapy.

Conclusion

Leflunomide was well tolerated and successful in preventing recurrence of viremia in renal transplant recipients with resistant CMV infection. The beneficial effect of leflunomide in this setting warrants further investigation.

Schlagwörter

Stichwörter der Autor:innen

Cytomegalovirus infectionLeflunomideRenal transplant recipients

Autor:innen und Institutionen

  • Section of Nephrology, University of Chicago, Chicago, Ill., USA.
  • Division of Nephrology and Transplant Medicine, University of Arizona, Tucson, Ariz., USA.
  • Section of Transplant Surgery, University of Chicago, Chicago, Ill., USA.
  • Section of Infectious Disease, University of Chicago, Chicago, Ill., USA.
  • Department of Pharmacy Services, University of Chicago, Chicago, Ill., USA.

Zitieren

APA

Chon, W. J., Kadambi, P. V., Xu, C., Becker, Y. T., Witkowski, P., Pursell, K., Kane, B., & Josephson, M. A. (2015). Use of Leflunomide in Renal Transplant Recipients with Ganciclovir-Resistant/Refractory Cytomegalovirus Infection: A Case Series from the University of Chicago. Case Reports in Nephrology and Dialysis, 5(1), 96-105. https://doi.org/10.1159/000381470

Vancouver

Chon WJ, Kadambi PV, Xu C, Becker YT, Witkowski P, Pursell K, et al. Use of Leflunomide in Renal Transplant Recipients with Ganciclovir-Resistant/Refractory Cytomegalovirus Infection: A Case Series from the University of Chicago. Case Reports in Nephrology and Dialysis. 2015;5(1):96-105. doi:10.1159/000381470

BibTeX
@article{Chon2015,
  author = {Chon, W James and Kadambi, Pradeep V and Xu, Chang and Becker, Yolanda T and Witkowski, Piotr and Pursell, Kenneth and Kane, Brenna and Josephson, Michelle A},
  title = {Use of Leflunomide in Renal Transplant Recipients with Ganciclovir-Resistant/Refractory Cytomegalovirus Infection: A Case Series from the University of Chicago},
  journal = {Case Reports in Nephrology and Dialysis},
  year = {2015},
  volume = {5},
  number = {1},
  pages = {96--105},
  doi = {10.1159/000381470}
}
Kostenlos starten →